Pharmacokinetics of rifampin in infants and children: Relevance to prophylaxis against Haemophilus influenzae type b disease

G. H. McCracken, C. M. Ginsburgh, T. C. Zweighaft, J. Clahsen

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Pharmacokinetic studies of rifampin were performed in 38 infants and children after administration of three different oral formulations. Mean peak serum concentrations of from 9 to 11.5 μg/ml were observed one hour after a 10-mg/kg dose and the average half-life was 2.9 hours. Patients who received rifampin suspension in applesauce had smaller serum concentrations and area-under-the-curve values than did those who sere given suspension alone. The mixture of rifampin powder and applesauce resulted in more variable serum levels. The concentrations of drug in tears from 18 subjects were similar to those in serum. All but one of 118 saliva specimens obtained from two to eight hours after the 10-mg/kg dose had antimicrobial activity. Of samples taken at two hours, 95% contained rifampin levels that exceeded the minimal bacterial concentration for 15 Haemophilus influenzae type b strains. Bactericidal activity against Haemophilus correlated with salivary rifampin concentrations and was detectable in virtually all specimens containing ≥0.8 μg/ml. These data provide the pharmacokinetics basis for rifampin prophylaxis of close contacts of H influenzae type b disease, but are insufficient alone to recommend routine usage of rifampin for this purpose until results of additional epidemiologic studies are available.

Original languageEnglish (US)
Pages (from-to)17-21
Number of pages5
JournalPediatrics
Volume66
Issue number1
StatePublished - 1980

Fingerprint

Haemophilus influenzae type b
Rifampin
Pharmacokinetics
Serum
Suspensions
Haemophilus
Tears
Saliva
Powders
Human Influenza
Area Under Curve
Half-Life
Epidemiologic Studies
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Pharmacokinetics of rifampin in infants and children : Relevance to prophylaxis against Haemophilus influenzae type b disease. / McCracken, G. H.; Ginsburgh, C. M.; Zweighaft, T. C.; Clahsen, J.

In: Pediatrics, Vol. 66, No. 1, 1980, p. 17-21.

Research output: Contribution to journalArticle

@article{a51f9dab665045e9a053b53bc4cc5902,
title = "Pharmacokinetics of rifampin in infants and children: Relevance to prophylaxis against Haemophilus influenzae type b disease",
abstract = "Pharmacokinetic studies of rifampin were performed in 38 infants and children after administration of three different oral formulations. Mean peak serum concentrations of from 9 to 11.5 μg/ml were observed one hour after a 10-mg/kg dose and the average half-life was 2.9 hours. Patients who received rifampin suspension in applesauce had smaller serum concentrations and area-under-the-curve values than did those who sere given suspension alone. The mixture of rifampin powder and applesauce resulted in more variable serum levels. The concentrations of drug in tears from 18 subjects were similar to those in serum. All but one of 118 saliva specimens obtained from two to eight hours after the 10-mg/kg dose had antimicrobial activity. Of samples taken at two hours, 95{\%} contained rifampin levels that exceeded the minimal bacterial concentration for 15 Haemophilus influenzae type b strains. Bactericidal activity against Haemophilus correlated with salivary rifampin concentrations and was detectable in virtually all specimens containing ≥0.8 μg/ml. These data provide the pharmacokinetics basis for rifampin prophylaxis of close contacts of H influenzae type b disease, but are insufficient alone to recommend routine usage of rifampin for this purpose until results of additional epidemiologic studies are available.",
author = "McCracken, {G. H.} and Ginsburgh, {C. M.} and Zweighaft, {T. C.} and J. Clahsen",
year = "1980",
language = "English (US)",
volume = "66",
pages = "17--21",
journal = "Pediatrics",
issn = "0031-4005",
publisher = "American Academy of Pediatrics",
number = "1",

}

TY - JOUR

T1 - Pharmacokinetics of rifampin in infants and children

T2 - Relevance to prophylaxis against Haemophilus influenzae type b disease

AU - McCracken, G. H.

AU - Ginsburgh, C. M.

AU - Zweighaft, T. C.

AU - Clahsen, J.

PY - 1980

Y1 - 1980

N2 - Pharmacokinetic studies of rifampin were performed in 38 infants and children after administration of three different oral formulations. Mean peak serum concentrations of from 9 to 11.5 μg/ml were observed one hour after a 10-mg/kg dose and the average half-life was 2.9 hours. Patients who received rifampin suspension in applesauce had smaller serum concentrations and area-under-the-curve values than did those who sere given suspension alone. The mixture of rifampin powder and applesauce resulted in more variable serum levels. The concentrations of drug in tears from 18 subjects were similar to those in serum. All but one of 118 saliva specimens obtained from two to eight hours after the 10-mg/kg dose had antimicrobial activity. Of samples taken at two hours, 95% contained rifampin levels that exceeded the minimal bacterial concentration for 15 Haemophilus influenzae type b strains. Bactericidal activity against Haemophilus correlated with salivary rifampin concentrations and was detectable in virtually all specimens containing ≥0.8 μg/ml. These data provide the pharmacokinetics basis for rifampin prophylaxis of close contacts of H influenzae type b disease, but are insufficient alone to recommend routine usage of rifampin for this purpose until results of additional epidemiologic studies are available.

AB - Pharmacokinetic studies of rifampin were performed in 38 infants and children after administration of three different oral formulations. Mean peak serum concentrations of from 9 to 11.5 μg/ml were observed one hour after a 10-mg/kg dose and the average half-life was 2.9 hours. Patients who received rifampin suspension in applesauce had smaller serum concentrations and area-under-the-curve values than did those who sere given suspension alone. The mixture of rifampin powder and applesauce resulted in more variable serum levels. The concentrations of drug in tears from 18 subjects were similar to those in serum. All but one of 118 saliva specimens obtained from two to eight hours after the 10-mg/kg dose had antimicrobial activity. Of samples taken at two hours, 95% contained rifampin levels that exceeded the minimal bacterial concentration for 15 Haemophilus influenzae type b strains. Bactericidal activity against Haemophilus correlated with salivary rifampin concentrations and was detectable in virtually all specimens containing ≥0.8 μg/ml. These data provide the pharmacokinetics basis for rifampin prophylaxis of close contacts of H influenzae type b disease, but are insufficient alone to recommend routine usage of rifampin for this purpose until results of additional epidemiologic studies are available.

UR - http://www.scopus.com/inward/record.url?scp=0018953735&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018953735&partnerID=8YFLogxK

M3 - Article

C2 - 6967586

AN - SCOPUS:0018953735

VL - 66

SP - 17

EP - 21

JO - Pediatrics

JF - Pediatrics

SN - 0031-4005

IS - 1

ER -